Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
- PMID: 3124975
- DOI: 10.1161/01.cir.77.3.678
Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
Abstract
Human recombinant tissue-type plasminogen activator (rt-PA) has been shown to be an effective and safe agent for coronary thrombolysis in patients with acute myocardial infarction. However, thrombolysis is associated with a high rate of acute reocclusion after discontinuation of rt-PA. The goals of the present study were to assess whether reocclusion after thrombolysis is caused by intracoronary platelet aggregation and to determine the role of thromboxane A2 (TxA2) and serotonin (5HT) in mediating this phenomenon. Accordingly, coronary thrombosis was induced in anesthetized, open-chest dogs by insertion of a copper coil into the left anterior descending coronary artery (LAD). LAD blood flow was monitored throughout the experiment by means of a Doppler flow probe placed proximally to the coil. Thrombolysis was achieved with rt-PA (0.05 mg/kg bolus + micrograms/kg/min infusion) in 23 +/- 3 min. rt-PA was then discontinued and each animal received a bolus of heparin (150 U/kg) every hour. Reperfusion was followed by repeated cycles of gradual occlusions followed by spontaneous restorations of blood flow (cyclic flow variations, CFVs) before a persistent occlusion recurred. In control dogs (n = 6), heparin alone did not prevent CFVs and reocclusion time was 25 +/- 4 min. Administration of an intravenous bolus of 0.2 +/- 0.06 mg/kg SQ29548, a TxA2/prostaglandin H2-receptor antagonist, and an intravenous bolus of 0.2 +/- 0.04 mg/kg ketanserin, a 5HT2-receptor antagonist, completely abolished CFVs in six of six dogs and reocclusion time was greater than 158 +/- 14 min (p less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.Circulation. 1989 Apr;79(4):911-9. doi: 10.1161/01.cir.79.4.911. Circulation. 1989. PMID: 2494005
-
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.J Clin Invest. 1990 Oct;86(4):1095-102. doi: 10.1172/JCI114813. J Clin Invest. 1990. PMID: 2145320 Free PMC article.
-
Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.Circ Res. 1989 Jul;65(1):83-94. doi: 10.1161/01.res.65.1.83. Circ Res. 1989. PMID: 2500270
-
Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.Mol Biol Med. 1991 Apr;8(2):235-43. Mol Biol Med. 1991. PMID: 1806765 Review.
-
[Pathophysiology and treatment of thrombosis. 3. Prevention and treatment of thrombosis. (1) The role of intracoronary thrombi, platelet function and prostaglandins in the pathogenesis of myocardial infarction; with special reference to intracoronary thrombolysis treatment].Nihon Naika Gakkai Zasshi. 1987 Jan;76(1):43-8. doi: 10.2169/naika.76.43. Nihon Naika Gakkai Zasshi. 1987. PMID: 3553380 Review. Japanese. No abstract available.
Cited by
-
Guidelines for the Management of Patients with Acute Myocardial Infarction.J Thromb Thrombolysis. 1998;5(1):73-81. doi: 10.1023/A:1008809723703. J Thromb Thrombolysis. 1998. PMID: 10608054 No abstract available.
-
Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.J Thromb Thrombolysis. 1997;4(2):259-266. doi: 10.1023/a:1008899002382. J Thromb Thrombolysis. 1997. PMID: 10639267
-
Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.Br J Pharmacol. 1992 Aug;106(4):917-23. doi: 10.1111/j.1476-5381.1992.tb14435.x. Br J Pharmacol. 1992. PMID: 1393289 Free PMC article.
-
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.Proc Natl Acad Sci U S A. 1989 Oct;86(19):7585-9. doi: 10.1073/pnas.86.19.7585. Proc Natl Acad Sci U S A. 1989. PMID: 2508092 Free PMC article.
-
Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.Br J Pharmacol. 1994 May;112(1):272-6. doi: 10.1111/j.1476-5381.1994.tb13063.x. Br J Pharmacol. 1994. PMID: 8032650 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources